Fig. 1Heterogeneity of immunophenotypically defined acute myeloid leukemia stem cells (AMLSCs) by CD34 and CD38. Figure shows results of flowcytometric analyses of 52 patients with treatment for näive acute myeloid leukemia (AML). X and y axes indicate CD34 and CD38 expression in primary AML cells of each patient, respectively. Some patients have abundant CD34+ cells, some patients have enriched CD34+CD38- cell fraction, and other patients have few CD34+CD38- cells, which shows remarkable heterogeneity. Adapted with permission from in Han et al. [33] Leukemic stem cell phenotype is associated with mutational profile in acute myeloid leukemia. Korean J Int Med 2021;36:401-2.

© Blood Research